Iruzid (Hydrochlorothiazide, Lisinopril)

Lisinopril inhibits the angiotensin‑converting enzyme, decreasing angiotensin II production and causing blood vessels to relax. Hydrochlorothiazide blocks sodium reabsorption in the distal kidney tubules, increasing urine output and reducing fluid volume. Together, they lower blood pressure by reducing both vascular tone and circulating fluid.

The specific dose of Iruzid is determined by the prescribing clinician based on the individual’s blood‑pressure readings, renal function, and overall health status. Only a qualified healthcare professional can set the appropriate dosage regimen for each patient.

Safety of Iruzid in pregnancy or while breastfeeding has not been established. Healthcare providers usually avoid ACE inhibitors and thiazide diuretics during the first trimester and advise caution throughout pregnancy. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative treatments with their physician.

To request Iruzid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iruzid combines two well‑established mechanisms—ACE inhibition and thiazide diuresis—into a single tablet, offering convenience over taking separate agents. Compared with monotherapy, the combination can achieve better blood‑pressure control with fewer pills, but individual tolerability and specific patient factors may make other classes (e.g., ARBs or calcium‑channel blockers) preferable in some cases.

Iruzid tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Iruzid is taken orally, usually once daily or as directed by a healthcare professional. The tablet should be swallowed whole with a full glass of water, and it can be taken with or without food unless the prescriber advises otherwise.

The most serious risks include angioedema (rapid swelling of the face, lips, tongue, or throat), severe dehydration or electrolyte imbalance, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, sudden weight loss, persistent vomiting, or a marked decline in kidney function.

Iruzid should be avoided in individuals with known hypersensitivity to either lisinopril or hydrochlorothiazide, a history of angioedema related to ACE inhibitors, severe renal impairment, or significant electrolyte disturbances. Pregnant women, especially in the first trimester, should also refrain from using this medication unless specifically directed by a physician.